

Study and Trial Names

Acronym	Name
ACTG	AIDS Clinical Trials Group
AMP	Adolescent Master Protocol
ANRS	National Agency for AIDS Research (France)
ARROW	AntiRetroviral Research fOr Watoto
ATHENA	AIDS Therapy Evaluation in the Netherlands
ATLAS	Antiretroviral Therapy as Long-Acting Suppression
BAN	Breastfeeding, Antiretrovirals, and Nutrition
CHAPAS	Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens
CHER	Children with HIV Early Antiretroviral Therapy
DolPHIN-2	Dolutegravir in Pregnant HIV Mothers and Their Neonates
ECHO	Evidence for Contraceptive Options and HIV Outcomes
ENCORE	Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy
EPIICAL	Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies
EPPICC	European Pregnancy and Paediatric Infections Cohort Collaboration
FLAIR	First Long-Acting Injectable Regimen
HPTN	HIV Prevention Trials Network
leDEA	International Epidemiology Databases to Evaluate AIDS
IMPAACT	International Maternal Pediatric Adolescent AIDS Clinical Trials
LATTITUDE	Long-Acting Therapy to Improve Treatment Success in Daily Life
MOCHA	More Options for Children and Adolescents
NADIA	Nucleosides And Darunavir/Dolutegravir in Africa
NEVEREST	Nevirapine Resistance Study
ODYSSEY	Once-daily DTG based ART in Young people vS Standard thErapY
PACTG	Pediatric AIDS Clinical Trials Group
PAINT	Pediatric Study in Adolescents Investigating a New NNRTI TMC278
PENPACT	Trial run in collaboration between PENTA and PACTG/IMPAACT
PENTA	Paediatric European Network for Treatment of AIDS
PHACS	Pediatric HIV/AIDS Cohort Study
PIANO	Paediatric study of Intence As an NNRTI Option
PREDICT	Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV
PROMISE	Promoting Maternal and Infant Survival Everywhere Study
PROMOTE	PEPFAR PROMise Ongoing Treatment Evaluation

SBIRT	Screening, Brief Intervention, and Referral to Treatment
SMILE	Strategy for Maintenance of HIV Suppression with Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children
START	Strategic Timing of AntiRetroviral Treatment
SWORD-1 and SWORD-2	Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults
THRIVE	TMC278 against HIV, in a once-daily Regimen Versus Efavirenz